J&J's TMC435 Joins The Pharmasset Club
Pharmasset and J&J's Tibotec unit will initiate a Phase II study evaluating the combination of the investigational nucleotide polymerase inhibitor PSI-7977 and protease inhibitor TMC435.
Pharmasset and J&J's Tibotec unit will initiate a Phase II study evaluating the combination of the investigational nucleotide polymerase inhibitor PSI-7977 and protease inhibitor TMC435.